Omega Therapeutics Q1 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate, Sales $2.360M Beat $1.630M Estimate
Portfolio Pulse from Benzinga Newsdesk
Omega Therapeutics (NASDAQ:OMGA) reported Q1 2024 earnings with a GAAP EPS of $(0.36), missing the $(0.35) estimate, but sales of $2.360M exceeded the $1.630M estimate, marking a 357.36% increase from the previous year.
May 06, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Omega Therapeutics reported a Q1 2024 GAAP EPS of $(0.36), missing estimates by 2.86%, but sales of $2.360M exceeded expectations by 44.79%, a significant increase from the previous year.
While the EPS miss might concern some investors, the substantial beat on sales and the impressive year-over-year growth could signal strong underlying business performance. The mixed results could lead to neutral short-term stock price movement as investors weigh the EPS miss against the sales beat and growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100